Details

PDF BIBTEX RIS

Title

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

Journal title

Polish Journal of Veterinary Sciences

Yearbook

2023

Volume

vol. 26

Issue

No 3

Authors

Szczubiał, M. ; Łopuszyński, W. ; Dąbrowski, R. ; Jamioł, M. ; Bochniarz, M. ; Brodzki, P.

Affiliation

Szczubiał, M. : Department and Clinic of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences, Gleboka 30, 20-612 Lublin, Poland ; Dąbrowski, R. : Department and Clinic of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences, Gleboka 30, 20-612 Lublin, Poland ; Bochniarz, M. : Department and Clinic of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences, Gleboka 30, 20-612 Lublin, Poland ; Brodzki, P. : Department and Clinic of Animal Reproduction, Faculty of Veterinary Medicine, University of Life Sciences, Gleboka 30, 20-612 Lublin, Poland ; Łopuszyński, W. : Department of Pathomorphology and Forensic Veterinary Medicine, Faculty of Veterinary Medicine, University of Life Sciences, Gleboka 30, 20-612 Lublin, Poland ; Jamioł, M. : Department of Animal Biochemistry, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 12, 20-033 Lublin, Poland

Keywords

canine mammary tumours ; CCL2 ; chemokines ; CXCL12 ; metastases ; plasma

Divisions of PAS

Nauki Biologiczne i Rolnicze

Coverage

385–392

Publisher

Polish Academy of Sciences Committee of Veterinary Sciences ; University of Warmia and Mazury in Olsztyn

Bibliography


  1. Abdelmegeed SM, Mohammed S (2018) Canine mammary tumors as a model for human disease. Oncol Lett 15: 8195-8205.
  2. Aljurany AN, Samarrai OR (2022) Evaluation of chemokine CXCL12 level with oxidative stress in breast cancer. Int J Health Sci 6: 6382-6392.
  3. Allende C, Higgins B, Johns J (2020) Comparison of serum cytokine concentrations between healthy dogs and canine osteosarcoma patients at the time of diagnosis. Vet Immunol Immunopathol 227: 110084.
  4. Ariyarathna H, Thomson N, Aberdein D, Munday JS (2020) Chemokine gene expression influences metastasis and survival time of female dogs with mammary carcinoma. Vet Immunol Immunopathol 227: 110075.
  5. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE (2007) Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17: 687-694.
  6. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313-326.
  7. Elston CW, Ellis IO (1998) Assessment of histological grade. In: Systemic Pathology. Churchill Livingstone, London, pp 356-384.
  8. Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, Liu L (2020) Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Acta Gastroenterol Belg 83: 295-299.
  9. Ferrari SM, Elia G, Piaggi S, Baldini E, Ulisse S, Miccoli M, Materazzi G, Antonelli A, Fallahi P (2018) CCL2 is modulated by cytokines and PPAR-γ in anaplastic thyroid cancer. Anticancer Agents Med Chem 18: 458-466.
  10. Gao D, Fish EN (2018) Chemokines in breast cancer: Regulating metabolism. Cytokine 109: 57-64.
  11. Goldschmidt M, Pena L, Rasotto R, Zappulli V (2011) Classification and grading of canine mammary tumors. Vet Pathol 48: 117-131.
  12. Hayasaka H, Yoshida J, Kuroda Y, Nishiguchi A, Matsusaki M, Kishimoto K, Nishimura H, Okada M, Shimomura Y, Kobayashi D, Shimazu Y, Taya Y, Akashi M, Miyasaka M (2022) CXCL12 promotes CCR7 ligand-mediated breast cancer cell invasion and migration toward lymphatic vessels. Cancer Sci 113: 1338-1351.
  13. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C (1999) Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859.
  14. Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH (2017) Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol 15: 315-327.
  15. Ishioka K, Suzuki Y, Tajima K, Ohtaki S, Miyabe M, Takasaki M, Mori A, Momota Y, Azakami D, Sako T (2013) Monocyte chemoattractant protein-1 in dogs affected with neoplasia or inflammation. J Vet Med Sci 75: 173-177.
  16. Janssens R, Struyf S, Proost P (2018) The unique structural and functional features of CXCL12. Cell Mol Immunol 15: 299-311.
  17. Kohli K, Pillarisetty VG, Kim TS (2022) Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 29: 10-21.
  18. Li H, Wu M, Zhao X (2022) Role of chemokine systems in cancer and inflammatory diseases. MedComm 3: e147.
  19. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ (2016) Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7: 28697-28710.
  20. Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284: 29087-29096.
  21. Lu X, Qian CN, Mu YG, Li NW, Li S, Zhang HB, Li SW, Wang FL, Guo X, Xiang YQ (2011) Serum CCL2 and serum TNF-α – Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer 47: 339-346.
  22. Lubowicka E, Przylipiak A, Zajkowska M, Piskór BM, Malinowski P, Fiedorowicz W, Ławicki S (2018) Plasma chemokine CCL2 and its receptor CCR2 concentrations as diagnostic biomarkers for breast cancer patients. Biomed Res Int 2018: 2124390.
  23. Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, Watari K, Takeuchi H, Takagi S, Hosoya K, Kim S, Ohta H, Kato Y, Suzuki Y, Murata S, Ohashi K (2022) Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep 12: 9265.
  24. Marques CS, Santos AR, Gameiro A, Correia J, Ferreira F (2018) CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors. BMC Cancer 18: 741.
  25. Marques CS, Soares M, Santos A, Correia J, Ferreira F (2017) Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes. Oncotarget 8: 105775-105789.
  26. Nielsen LN, Kjelgaard-Hansen M, Kristensen AT (2013) Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese Mountain dogs with disseminated histiocytic sarcoma. Vet J 198: 424-428.
  27. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
  28. Pan YW, Zhou ZG, Wang M, Dong JQ, Du KP, Li S, Liu YL, Lv PJ, Gao JB (2016) Combination of IL6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. Genet Mol Res 15: gmr15048949.
  29. Pena L, De Andres PJ, Clemente M, Cuesta P, Perez-Alenza MD (2013) Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet Pathol 50: 94-105.
  30. Perry JA, Thamm DH, Eickhoff J, Avery AC, Dow SW (2011) Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Vet Comp Oncol 9: 55-64.
  31. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
  32. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256: 137-165.
  33. Rybicka A, Eyileten C, Taciak B, Mucha J, Majchrzak K, Hellmen E, Krol M (2016) Tumour-associated macrophages influence canine mammary cancer stem-like cells enhancing their pro-angiogenic properties. J Physiol Pharmacol 67: 491-500.
  34. Salas Y, Marquez A, Diaz D, Romero L (2015) Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: a growing animal health problem. PLoS One 10: e0127381.
  35. Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117: 88-97.
  36. Shi Y, Riese DJ 2nd, Shen J (2020) The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol 11: 574667.
  37. Shimizu N, Hamaide A, Dourcy M, Noёl S, Clercx C, Teske E (2019) Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours. Vet Comp Oncol 17: 11-20.
  38. Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L (2011) Canine mammary tumours, an overview. Reprod Domest Anim 46: 1112-1131.
  39. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285.
  40. Tang CH, Tsai CC (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Biochem Pharmacol 83: 335-344.
  41. Wu J, Liu X, Wang Y (2013) Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer. BMC Clin Pathol 13: 15.
  42. Yao M, Yu E, Staggs V, Fan F, Cheng N (2016) Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod Pathol 29: 810-823.
  43. Zielińska KA, Katanaev VL (2020) The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis. Cancers (Basel) 12: 3071.

Type

Article

Identifier

DOI: 10.24425/pjvs.2023.145044
×